Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothGMP APIs & Flow Chemistry from a Leader in the Healthcare & Wellbeing market in the Pharma & Mass-market sectors

            Contact the Supplier

            Lead Product(s): Lurasidone HCl

            Therapeutic Area: Psychiatry/Psychology Product Name: Latuda

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sunovion Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 12, 2020

            Details:

            Latuda becomes the first 2nd generation antipsychotic to be approved for patients suffering from schizophrenia as young as 13 years of age. In addition to the new indication, Latuda was also granted an additional year of marketing protection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Buprenorphine Hydrochloride,Naloxone Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: Zubsolv

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ACCORD HEALTHCARE

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 07, 2020

            Details:

            Under the terms of the agreement, Orexo will be responsible for product supply and Accord will take responsibility for the commercialisation of ZUBSOLV®. Orexo will receive double-digit royalties on future net sales.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lidocaine,Prilocaine

            Therapeutic Area: Psychiatry/Psychology Product Name: Senstend

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Wanbang Biopharmaceuticals

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 02, 2020

            Details:

            Under the License Agreement Regent Pacific is now entitled to receive a payment of approximately HK$6.24 million from Wanbang Pharmaceutical, which is payable within 30 business days. NMPA will now formally review Senstend™ for Clinical Trial Approval.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Quetiapine Fumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Distriphil

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 26, 2020

            Details:

            Luye Pharma grants Distriphil the exclusive distribution and marketing rights for the central nervous system drugs Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in the Philippines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Methylphenidate Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: Quillivant XR

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Medison Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 17, 2020

            Details:

            Under the terms of the licensing agreement, Medison has been granted exclusive rights to commercialize Tris’ FDA-approved Quillivant XR in Israel.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Risperidone

            Therapeutic Area: Psychiatry/Psychology Product Name: Perseris

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 17, 2020

            Details:

            Health Canada has approved HLS Therapeutics' PERSERIS® (risperidone for extended-release injectable suspension), 90 mg and 120 mg subcutaneous injection, a novel long-acting injectable of risperidone, for the treatment of schizophrenia in adults.

            Federal Emergency Management Agency

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lofexidine Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: Lucemyra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: US WorldMeds

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 06, 2020

            Details:

            US WorldMeds, in conjunction with FEMA and their partnership with Healthcare Ready, is making a donation of LUCEMYRA valued at approximately $100,000 to NorthLakes Community Clinic, a federally qualified health center located in northern Wisconsin.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Methylphenidate

            Therapeutic Area: Psychiatry/Psychology Product Name: Concerta

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 29, 2020

            Details:

            The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aripiprazole

            Therapeutic Area: Psychiatry/Psychology Product Name: Abilify Maintena

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 26, 2020

            Details:

            Otsuka Pharmaceutical created ABILFY MAINTENA, an atypical antipsychotic, which first received regulatory approval in 2013 in the U.S. and E.U. for the treatment of adult schizophrenia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Buprenorphine

            Therapeutic Area: Psychiatry/Psychology Product Name: Sixmo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Molteni Farmaceutici

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 14, 2020

            Details:

            Under the terms of the agreement, Accord will commercialize Sixmo®▼ (buprenorphine implant), an opioid agonist therapy treatment, delivered through a first-of-its-kind implant, placed under the skin for six-months.